Polypharmacy, generally defined in research as the regular use of five or more medications, has become a defining feature of aging in modern healthcare systems, and it is far more common than most people realize. Studies of prescribing patterns among older adults have found that a substantial share of people over sixty-five take five or more medications regularly, with a smaller but significant portion taking ten or more, often accumulated gradually across years of visits to different specialists, each adding a medication to address a specific concern without necessarily reviewing the full list a patient is already managing. The result is medication regimens that can become genuinely difficult for patients to follow correctly and that carry cumulative risks research has only recently begun to quantify carefully.
Why Polypharmacy Becomes Dangerous
The clinical concern with polypharmacy is not that any single medication is inappropriate in isolation, but that the interactions and cumulative burden of many medications together create risks that exceed the sum of their individual profiles. Research on adverse drug events has consistently found that the risk of a harmful drug interaction or side effect rises sharply as the number of concurrent medications increases, and that older adults are particularly vulnerable because age-related changes in kidney and liver function alter how drugs are metabolized and cleared from the body, meaning a dose that was appropriate at a younger age may become excessive over time even without any change in prescription. Studies of hospital admissions among older adults have found that adverse drug events are a common and often preventable cause of emergency visits and hospitalizations in this population, frequently involving medications that had been prescribed appropriately at some point but were never reassessed as circumstances changed.
Drug Classes of Greatest Concern
Certain drug classes appear disproportionately in research on medication-related harm in older adults. Sedatives and sleep medications are associated with increased fall risk, a particularly consequential outcome in older adults given that falls are a leading cause of injury-related hospitalization and can trigger a cascade of functional decline. Anticholinergic medications, used for a wide range of conditions including allergies, bladder control, and depression, have been linked in multiple longitudinal studies to increased risk of cognitive impairment with cumulative long-term use, a finding that has prompted particular caution around prescribing these drugs to older patients when alternatives exist. Certain blood pressure and diabetes medications, when dosed based on standards developed primarily from younger and middle-aged research populations, can produce dangerously low blood pressure or blood sugar in frail older adults, sometimes with a different appropriate target than the drug's original approval studies would suggest.
What Deprescribing Actually Involves
Deprescribing has emerged as the term researchers use for the systematic, supervised process of tapering or stopping medications that are no longer providing net benefit, whether because the original condition has resolved, because the risks of continued use now outweigh the benefits given a patient's current health status and life expectancy, or because a medication is duplicating the effect of another drug already being taken. This is a more deliberate process than simply telling a patient to stop taking something, and research emphasizes that deprescribing done carelessly carries its own risks, including withdrawal effects for certain medications and the return of symptoms the drug was originally managing. Structured deprescribing protocols, which involve a systematic medication review, explicit criteria for identifying candidates for discontinuation, and a gradual, monitored tapering process, have shown in clinical trials to reduce medication burden without a corresponding increase in adverse health outcomes, and in some studies have been associated with improved cognitive function and reduced fall risk following the reduction in sedating or anticholinergic medications.
Making Deprescribing Work in Practice
Comprehensive medication reviews, ideally conducted by a pharmacist working alongside a patient's primary physician, have consistently shown value in research as the starting point for safe deprescribing, since they create a structured opportunity to examine the full medication list against a patient's current diagnoses, functional status, and goals of care, rather than relying on the more fragmented review that tends to happen incidentally during routine visits focused on a single acute concern. Research has found that patients are often more receptive to reducing medications than clinicians assume, particularly when the conversation is framed around simplifying a complicated daily routine and reducing side-effect burden rather than around the idea that a doctor is taking something away.
The evidence base still has notable gaps, particularly around the longest-term outcomes of deprescribing programs and how to reliably identify which patients are the best candidates for medication reduction versus those who genuinely benefit from their current full regimen. Frailty and life expectancy considerations complicate the calculation further, since a preventive medication with benefits that accrue over many years may offer little practical value to a patient with a shorter remaining life expectancy, a nuanced judgment that requires individualized clinical reasoning rather than a one-size-fits-all protocol. What the current research supports fairly clearly is that unreviewed, accumulating medication lists carry real and often underappreciated risks for older adults, and that deliberate, clinician-guided deprescribing represents a meaningful and underused tool for reducing that risk without sacrificing the genuine benefits that appropriate medication use provides.
